Payment overview · 2025
General Payments
$134,063.77
141 reported records · 20 companies
Healthcare provider profile · identity verified
Eric H Liu, M.D.
Allopathic & Osteopathic Physicians|Surgery · DENVER, CO · NPI 1174763031
Verified facts
What the public records show
CMS Open Payments records show Eric H Liu, M.D. received $134,063.77 in general payments during 2025 across 141 reported records.
TerSera Therapeutics LLC accounted for 68.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Xermelo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Creon by this doctor in 2024.
TerSera Therapeutics LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xermelo as an associated drug or biological on 1332 records involving 974 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Xermelo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $91,862.14 | 68.5% | 31 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26,193.39 | 19.5% | 21 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $5,802.76 | 4.3% | 23 | 2025 |
| HISTOSONICS, INC. | Unresolved — no canonical attribution shown | $5,212.96 | 3.9% | 2 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $3,581.12 | 2.7% | 10 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $362.54 | 0.3% | 24 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $202.77 | 0.1% | 9 | 2025 |
| Davol Inc. | Unresolved — no canonical attribution shown | $150.26 | 0.1% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $137.94 | 0.1% | 2 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $111.34 | 0.1% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $97.20 | 0.1% | 2 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $73.73 | 0.1% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $65.14 | 0.1% | 3 | 2025 |
| Dilon Technologies, Inc. | Unresolved — no canonical attribution shown | $59.02 | 0.0% | 3 | 2025 |
| Surgical Specialties Corporation (us), Inc. (dba Corza Medical) | Unresolved — no canonical attribution shown | $39.83 | 0.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$32.63 | 0.0% | 1 | 2025 |
| BioCryst US Sales Co., LLC | Unresolved — no canonical attribution shown | $21.22 | 0.0% | 1 | 2025 |
| CONMED Corporation | Unresolved — no canonical attribution shown | $20.10 | 0.0% | 1 | 2025 |
| Curium US LLC | Unresolved — no canonical attribution shown | $19.71 | 0.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.97 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $90,245.00 | 7 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,100.00 | 8 |
| Travel and Lodging | $12,963.49 | 18 |
| Debt forgiveness | $3,980.00 | 1 |
| Food and Beverage | $3,775.28 | 107 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Xermelo Normalized: xermelo |
Drug | TerSera Therapeutics LLC | $47,019.93 | 27 | 2025 |
Source payment records
|
|||||
| Zoladex Normalized: zoladex |
Drug | TerSera Therapeutics LLC | $44,842.21 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21,793.39 | 19 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $5,802.76 | 23 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $3,406.21 | 9 | 2025 |
Source payment records
|
|||||
| Phasix Mesh Normalized: phasix mesh |
Device | Becton, Dickinson and Company, Davol Inc. | $185.15 | 3 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $111.38 | 1 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $111.34 | 1 | 2025 |
Source payment records
|
|||||
| VISTASEAL Normalized: vistaseal |
Biological | Ethicon US, LLC | $105.42 | 5 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $103.16 | 3 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $99.61 | 6 | 2025 |
Source payment records
|
|||||
| QUIKCLOT Normalized: quikclot |
Device | Teleflex LLC | $97.20 | 2 | 2025 |
Source payment records
|
|||||
| Echelon Flex Normalized: echelon flex |
Device | Ethicon US, LLC | $83.97 | 8 | 2025 |
Source payment records
|
|||||
| ETHICON Normalized: ethicon |
Device | Ethicon US, LLC | $70.95 | 4 | 2025 |
Source payment records
|
|||||
| STRATAFIX Normalized: stratafix |
Device | Ethicon US, LLC | $67.45 | 3 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $65.14 | 3 | 2025 |
Source payment records
|
|||||
| HEMOBLAST BELLOWS Normalized: hemoblast bellows |
Device | Dilon Technologies, Inc. | $59.02 | 3 | 2025 |
Source payment records
|
|||||
| SURGIFLO Hemostatic Matrix Normalized: surgiflo hemostatic matrix |
Device | Ethicon US, LLC | $57.13 | 3 | 2025 |
Source payment records
|
|||||
| Certus 140 Normalized: certus 140 |
Device | Ethicon US, LLC | $53.58 | 3 | 2025 |
Source payment records
|
|||||
| Harmonic Normalized: harmonic |
Device | Ethicon US, LLC | $39.63 | 3 | 2025 |
Source payment records
|
|||||
| Endopath Normalized: endopath |
Device | Ethicon US, LLC | $37.58 | 4 | 2025 |
Source payment records
|
|||||
| Proximate Normalized: proximate |
Device | Ethicon US, LLC | $35.43 | 3 | 2025 |
Source payment records
|
|||||
| Echelon Circular Normalized: echelon circular |
Device | Ethicon US, LLC | $33.99 | 4 | 2025 |
Source payment records
|
|||||
| EMPRINT Normalized: emprint |
Device | Medtronic, Inc. | $32.63 | 1 | 2025 |
Source payment records
|
|||||
| Echelon; Endopath Normalized: echelon endopath |
Device | Ethicon US, LLC | $30.58 | 2 | 2025 |
Source payment records
|
|||||
| Neuwave Normalized: neuwave |
Device | Ethicon US, LLC | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| ORLADEYO Normalized: orladeyo |
Drug | BioCryst US Sales Co., LLC | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| AIRSEAL Normalized: airseal |
Device | CONMED Corporation | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| Detectnet Normalized: detectnet |
Drug | Curium US LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| EVARREST Normalized: evarrest |
Biological | Ethicon US, LLC | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| SURGICEL NU-KNIT Normalized: surgicel nu knit |
Device | Ethicon US, LLC | $11.78 | 1 | 2025 |
Source payment records
|
|||||
| SmartAblateTM System RF Generator Normalized: smartablatetm system rf generator |
Device | Ethicon US, LLC | $10.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 69 | exact normalized | Medicare Part D |
| Xermelo xermelo |
2025 | Xermelo | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
| TerSera Therapeutics LLC Exact reporting entity; no affiliate inference |
2025 | Xermelo open payments reported associated product |
CMS Open Payments — General Payments 1332 supporting records · 974 recipient NPIs · example record 1244053204 |
Xermelo · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Creon | Lipase/Protease/Amylase | 69 | 19 |
| Somatuline Depot | Lanreotide Acetate | 47 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Xermelo | Telotristat Etiprate | 16 | suppressed |
| Octreotide Acetate | Octreotide Acetate | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $134,063.77 · 141 records | TerSera Therapeutics LLC | AIRSEAL, CABOMETYX, CREON, Certus 140, Detectnet, EMPRINT, ETHICON, EVARREST, Echelon Circular, Echelon Flex, Echelon; Endopath, Endopath, HEMOBLAST BELLOWS, Harmonic, ISTURISA, LUTATHERA, MI CANCER SEEK, Neuwave, ORLADEYO, PLUVICTO, Phasix Mesh, Proximate, QUIKCLOT, Restrata Wound Matrix, STRATAFIX, SURGICEL NU-KNIT, SURGIFLO Hemostatic Matrix, SmartAblateTM System RF Generator, VISTASEAL, WELIREG, Xermelo, ZEPZELCA, Zoladex | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error